Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Q&A with Daniel Drucker.

Daniel Drucker

    Med (New York, N.Y.)
    |September 14, 2024
    PubMed
    Summary
    This summary is machine-generated.

    Professor Daniel Drucker reviews the history and future of glucagon-like peptide-1 (GLP-1) research. This discussion highlights key advancements and future directions in the field of GLP-1 therapeutics.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    QuNex recipes: Executable, human-readable workflows for reproducible neuroimaging research.

    Imaging neuroscience (Cambridge, Mass.)·2026
    Same author

    WDC15 Basic and Clinical Stream to offer extensive coverage on treatment advances.

    Diabetes research and clinical practice·2018
    Same author

    Endocrine Society 2014 Laureate Awards.

    Hormones & cancer·2014
    Same author

    Implications of the new Food and Drug Administration draft guidance on human factors engineering for diabetes device manufacturers.

    Journal of diabetes science and technology·2012
    Same author

    Sitagliptin.

    Nature reviews. Drug discovery·2007
    Same journal

    Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation.

    Med (New York, N.Y.)·2026
    Same journal

    Atlas of human brain imaging-derived phenotypes and disease risk.

    Med (New York, N.Y.)·2026
    Same journal

    Withdrawal effects following treatment discontinuation: A blind spot in evidence-based medicine.

    Med (New York, N.Y.)·2026
    Same journal

    Rethinking parenteral nutrition as supportive therapy for neonatal sepsis.

    Med (New York, N.Y.)·2026
    Same journal

    Power and sample-size estimation in human microbiome research.

    Med (New York, N.Y.)·2026
    Same journal

    Long-term remission of neuromyelitis optica with allogeneic hematopoietic stem cell transplant.

    Med (New York, N.Y.)·2026
    See all related articles

    Area of Science:

    • Endocrinology and Metabolism
    • Pharmacology

    Background:

    • Explores the historical development of glucagon-like peptide-1 (GLP-1) research.
    • Highlights foundational discoveries and early therapeutic explorations.

    Discussion:

    • Features insights from Professor Daniel Drucker on GLP-1 receptor agonists.
    • Covers the evolution of GLP-1 based therapies for metabolic diseases.

    Key Insights:

    • Discusses the significant impact of GLP-1 research on treating type 2 diabetes and obesity.
    • Emphasizes the translational success from basic science to clinical application.

    Outlook:

    • Projects future research trajectories and potential novel applications of GLP-1.
    • Considers the expanding therapeutic landscape for incretin-based therapies.